Sensory symptom profiles differ between trigeminal and thoracolumbar postherpetic neuralgia

Rehm, Stefanie; Groβkopf, Moritz; Kabelitz, Maria; Keller, Thomas; Freynhagen, Rainer; Tölle, Thomas R.; Baron, Ralf

doi:10.1097/pr9.0000000000000636

Cited by 9 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…His primary area of focus was centered on the utilization of Lidocaine for the purpose of pain management in patients with PHN, as well as the significance of sensory symptom characteristics about PHN. [ 49 , 50 ] The individual with the highest number of citations was DWORKIN RH. His investigation encompasses various facets, including the diagnosis, prevention, treatment, and risk factors associated with PHN.…”

Section: Discussionmentioning

confidence: 99%

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

He,

Miao

et al. 2023

Medicine

View full text Add to dashboard Cite

Postherpetic neuralgia (PHN) represents a notable clinical challenge as it is the most prevalent and severe complication of herpes zoster (HZ). The primary objective was to investigate the current research status and hotspots of PHN research during the period from 2000 to 2022. The literature pertaining to PHN was gathered through the utilization of the Web of Science Core Collection, spanning from January 2000 to December 2022. The software, CiteSpace version 6.2.R2, was employed to produce visual depictions of publications related to PHN across various dimensions such as year, country/region, institution, journal, author, keyword, and reference. This study involved a total of 3505 papers. The USA held a dominant position in the production of scholarly articles. Argentina exhibited the highest frequency of participation in international collaboration. Out of all the institutions, Pfizer exhibited the highest degree of productivity. Harvard University exhibited the highest frequency of participation in international collaboration. The Pain exhibited the most noteworthy productivity rate and citation count among all other journals. Ralf Baron was identified as the most productive author, whereas DWORKIN RH attained the highest citation count. Contemporary scholarly investigations are predominantly centered on identifying risk factors, devising preventative measures, and exploring novel and secure methods of pain management. The current investigation has revealed the focal areas and patterns of studies pertaining to PHN. Presently, the research in this field is focused on identifying the risk factors and preventive measures for PHN, alongside exploring novel and secure pain management strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

He,

Miao

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…Trigeminal herpes zoster with symptoms of severe pain has a high probability of developing into PHN (Nagasako et al, 2002). The pain from trigeminal herpes is different from PHN in other areas of the body (Siviero et al, 2011; Rehm et al, 2018); it is more difficult to treat and requires medical attention. Drugs and nerve blocks are the usual courses of treatment to relieve pain.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of CT Guided Pulsed Radiofrequency Treatment for Trigeminal Postherpetic Neuralgia

Ding

Hong

et al. 2019

Front. Neurosci.

View full text Add to dashboard Cite

Objectives Trigeminal postherpetic neuralgia (TPHN) often presents with moderate to severe pain, hyperalgesia, and allodynia. Conventional analgesic treatments are poorly effective, which seriously affects the quality of life. This retrospective study aimed to evaluate the efficacy of pulsed radiofrequency (PRF) for the treatment of TPHN. Methods A total of 90 TPHN patients were selected between January 2014 and December 2016 in the Department of Pain Management, Shengjing Hospital, China Medical University. Patients were randomly divided into two groups according to the order of enrollment ( n = 45 per group): group A, peripheral nerve (supraorbital nerve, infraorbital nerve and mental nerve) PRF; group B, gasserian ganglion PRF. Follow-up assessments of visual analogue scale (VAS) pain assessment, SF-36 health status questionnaire, total efficiency rate, and drug dosage of anticonvulsants and opioid analgesics were performed at time points of 1 week, 1 month, 3 months, 6 months, and 1 year after surgery. Results At each postsurgery time point, the VAS decreased, SF-36 (physical and mental components) increased, and drug dosage of anticonvulsants and opioids analgesics decreased in both treatment groups; values at each time point were significantly different from presurgery values ( P < 0.05). Compared with group A, VAS decreased, SF-36 increased, and dosage of anticonvulsants and opioids analgesics decreased significantly in group B ( P < 0.05). The total efficiency rates one year after surgery in group A and group B were 68.9 and 86.7%, respectively. The total efficiency rate of group B was statistically higher than that of group A ( P < 0.05). Conclusion PRF relieved TPHN, and gasserian ganglion PRF was more effective than peripheral nerve PRF. The method was effective and improved the quality of life of the patients. PRF is recommended as a treatment for TPHN.

show abstract

“…In several animal models of sciatic nerve neuropathic pain, antagonizing ROS by administering antioxidants systemically or intrathecally reduces hyperalgesia and relieves allodynia ( 27 , 32 ). However, the sciatic and trigeminal nerves diverge functionally and transcriptionally in response to painful stimuli, with injury to trigeminal neurons being more intense and more difficult to treat ( 33 , 34 ).…”

Section: Introductionmentioning

confidence: 99%

Identification of the NRF2 transcriptional network as a therapeutic target for trigeminal neuropathic pain

Vasavda

Liew

et al. 2022

Sci. Adv.

View full text Add to dashboard Cite

Trigeminal neuralgia, historically dubbed the “suicide disease,” is an exceedingly painful neurologic condition characterized by sudden episodes of intense facial pain. Unfortunately, the only U.S. Food and Drug Administration (FDA)–approved medication for trigeminal neuralgia carries substantial side effects, with many patients requiring surgery. Here, we identify the NRF2 transcriptional network as a potential therapeutic target. We report that cerebrospinal fluid from patients with trigeminal neuralgia accumulates reactive oxygen species, several of which directly activate the pain-transducing channel TRPA1. Similar to our patient cohort, a mouse model of trigeminal neuropathic pain also exhibits notable oxidative stress. We discover that stimulating the NRF2 antioxidant transcriptional network is as analgesic as inhibiting TRPA1, in part by reversing the underlying oxidative stress. Using a transcriptome-guided drug discovery strategy, we identify two NRF2 network modulators as potential treatments. One of these candidates, exemestane, is already FDA-approved and may thus be a promising alternative treatment for trigeminal neuropathic pain.

show abstract

Sensory symptom profiles differ between trigeminal and thoracolumbar postherpetic neuralgia

Abstract: Differences in somatosensory profiles in different localisations in 1 distinct disease (postherpetic neuralgia) were shown. This might have implications for future research and treatment regimes.

Cited by 9 publications

References 20 publications

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

A bibliometric and visualization analysis of global research on postherpetic neuralgia from 2000 to 2022: A review

Efficacy of CT Guided Pulsed Radiofrequency Treatment for Trigeminal Postherpetic Neuralgia

Identification of the NRF2 transcriptional network as a therapeutic target for trigeminal neuropathic pain

Contact Info

Product

Resources

About